VENUE
The Banquet Hall, Level 3
Ritz-Carlton Hotel
168 Jalan Imbi
Kuala Lumpur, 55100
Malaysia

With the support of

[NIH logo]
[anRS logo]
[CIHR IRSC logo]
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>WELCOME STATEMENT</td>
<td>3</td>
</tr>
<tr>
<td><strong>SATURDAY 29 JUNE 2013</strong></td>
<td>4</td>
</tr>
<tr>
<td>Opening Session</td>
<td>4</td>
</tr>
<tr>
<td>Cellular sensing and regulation of HIV production</td>
<td>4</td>
</tr>
<tr>
<td>Roundtable: Pharma collaboration and regulatory issues</td>
<td>6</td>
</tr>
<tr>
<td>Characterizing the reservoir in tissues and T cell subsets</td>
<td>6</td>
</tr>
<tr>
<td><strong>SUNDAY 30 JUNE 2013</strong></td>
<td>8</td>
</tr>
<tr>
<td>Kick and Kill: novel approaches to reversing latency and immune clearance</td>
<td>8</td>
</tr>
<tr>
<td>Clinical interventions targeting the HIV reservoir</td>
<td>9</td>
</tr>
<tr>
<td>Roundtable: Ethics and patient expectations</td>
<td>10</td>
</tr>
<tr>
<td>Closing Session</td>
<td>10</td>
</tr>
<tr>
<td><strong>POSTER EXHIBITION – List of abstracts displayed</strong></td>
<td>11</td>
</tr>
<tr>
<td><strong>PROGRAMME COMMITTEE</strong></td>
<td>17</td>
</tr>
<tr>
<td><strong>PROGRAMME AT A GLANCE</strong></td>
<td>18</td>
</tr>
</tbody>
</table>

DOWNLOAD THE SYMPOSIUM ABSTRACT BOOK DIRECTLY USING THE QR CODE OR VISIT www.towardsanhivcure.org
Under the auspices of the International AIDS Society, an international working group of researchers developed and published a Global Scientific Strategy: Towards an HIV Cure, which was launched at a scientific symposium immediately preceding the XIX International AIDS Conference in Washington, DC in July 2012. Following the success of the 2012 symposium, we are very pleased to organize a new symposium in 2013 to provide an interactive and informative meeting for basic and clinical researchers, social scientists and community members involved in HIV cure research world-wide.

The IAS intends to monitor the implementation of the strategy by encouraging the creation of international research alliances and the development of existing consortiums to work collaboratively on the priorities defined in the strategic plan. To encourage collaboration, the IAS has facilitated the creation of a number of smaller topic-specific working groups.

The Working Group on Ethics was established in April 2012 following broad stakeholder’s consultations on the Global Scientific Strategy, in which ethical issues were highlighted as a crucial area for further development of HIV cure research. In May 2013, the Working Group on Ethics published an article ‘Ethical Considerations for HIV Cure Research’ in a special edition on HIV Cure in Current Opinion in HIV and AIDS. The review focuses on the ethical and regulatory aspects in HIV cure research and includes ethical considerations on the development of HIV cure strategies.

The Working Group on Cost-Effectiveness addresses the questions of cost-effectiveness of different potential HIV cure strategies and is currently preparing an opinion piece to discuss the risks and benefits of the various approaches and the potential cost-effectiveness in different stages of the disease and settings.

A multinational academic and community-based research team, the Psychosocial Studies Group, is developing a multi-country project to assess the willingness of patients’ to participate in HIV cure-related strategies and the potential impact of an HIV cure from a social and behavioral sciences perspective.

The Industry Collaboration Group aims to bring together industry partners and cure researchers to facilitate and encourage interactions and collaborations. The Industry Collaboration Group is co-chaired by two academia representatives (David Margolis, University of North Carolina and Sharon Lewin, Monash University, Melbourne) and two industry representatives (Andrew Spaltenstein, GSK and Guenter Kraus, Janssen) and the aim of the group is to foster the involvement of industry to develop a safe, accessible and scalable cure for HIV.

Abstracts Embargo Policy

Most abstracts presented at the symposium will also be presented at the IAS 2013 Conference. The content of these abstracts is embargoed until the date and time of the actual presentation in the IAS 2013 Conference. Therefore information about abstracts accepted for inclusion at IAS 2013 may not be published, in any form, before the date and time of their presentation at the conference.
Welcome Statement

Dear Colleagues,

On behalf of the International AIDS Society (IAS), the Programme Committee, and all members of the Towards an HIV Cure initiative, it is our pleasure to welcome you to Kuala Lumpur for the 2013 Towards an HIV Cure Symposium.

The two-day symposium will include invited speakers, oral abstract presentations and roundtable discussions, to present and discuss the most recent HIV cure research. The symposium will be a platform for knowledge-sharing and an opportunity for discussion on the latest scientific results on viral persistence and HIV cure approaches. The symposium will bring together the international community to debate, discuss and network.

The symposium is open to senior, mid-career and junior scientists, clinical researchers, community representatives, research funding administrators and scientific journalists. The symposium places strong emphasis on ensuring representation of scientific excellence and community globally, with scholarships being provided to more than 50 participants worldwide.

The symposium is closely linked to the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). HIV cure research abstracts submitted to IAS 2013 were selected for presentation at the Towards an HIV Cure Symposium.

In order to disseminate the information shared at this symposium, the issues and findings will be disseminated through the publication of the presented abstracts on the IAS website.

We look forward to a thought-provoking and fruitful meeting.

Sincerely,

Pr. Françoise Barré-Sinoussi
Symposium Co-Chair
IAS President

Dr. Steven G. Deeks
Symposium Co-Chair

Pr. Sharon Lewin
Symposium Co-Chair
AIDS 2014 Local Co-Chair
SATURDAY 29TH JUNE

9.00 – 10.10 OPENING SESSION
Co-Chairs: Sharon Lewin, The Alfred Hospital, Monash University and Burnet Institute, Australia
           Steve Deeks, University of California, San Francisco, United States

9.00 – 9.15
Welcome Remarks
Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France
Jack Whitescarver, NIH-OAR, United States

9.15 – 9.55
Keynote Address
Towards a Cure for HIV-Infected Children: Hype and Hope
Deborah Persaud, John Hopkins University School of Medicine, United States

09.55 – 10.10
CNIHR Award Ceremony
Co-Chairs: Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France
           Jack Whitescarver, NIH-OAR, United States
In collaboration with the U.S. Centers for AIDS Research and the U.S. National Institutes of Health, the IAS awards for the third time the grant programme “Creative and Novel Ideas in HIV Research” (CNIHR). In 2013, the CNIHR grant programme supports scientists without prior experience in HIV cure research with the aim of supporting innovative approaches with the potential of contributing to the search for an HIV cure. Eleven research grants worth up to US$150,000 per year for one to two years will be awarded at IAS 2013. The initiative aims to foster cross-disciplinary research, promote novel ideas and aid in the success of investigators at an early career stage. CNIHR grantees from 2012 and 2013 together with their mentors will attend a training and networking programme organised in conjunction with IAS 2013.

10.10 – 10.30 Coffee Break

10.30 – 12.15 CELLULAR SENSING AND REGULATION OF HIV PRODUCTION
Co-Chairs: Damian Purcell, University of Melbourne, Australia
           Michaela Müller-Trutwin, Institut Pasteur, France

10.30 – 11.00
Overview Speaker
Double impact of CTIP2 on establishment and persistence of latency
Olivier Rohr, IUT Louis Pasteur, University of Strasbourg, Institut Universitaire de France, France
11.00 – 11.15
OA1-1
Viral protein U (Vpu) reduces innate sensing of human immunodeficiency virus type 1 (HIV-1)-infected T cells by plasmacytoid dendritic cells (pDCs) via a BST-2 dependent process
M.G. Bego, É. Bérubé-Côté, J. Mercier, É.A. Cohen
Canada

11.15 – 11.30
OA1-2
Dendritic cell-lymphocyte crosstalk stimulates HIV-1 replication
France
Under embargo until 3 July 2013

11.30 – 11.45
OA1-3
Cell-intrinsic HIV-1 immune responses in conventional dendritic cells from HIV-1 elite controllers
United States
Under embargo until 3 July 2013

11.45 – 12.00
OA1-4 LB
Sustained high levels of circulating Galectin-9 despite viral suppression among HIV infected elite controllers
United States
Under embargo until 3 July 2013

12.00 – 12.15
OA1-5 LB
Teaching new dogs new tricks: An in vitro model of autologous HIV-1 immunotherapy induces CTL from naïve precursors in subjects on ART
K. Smith, R. Mailliard, W. Jiang, J. Mullins, C. Rinaldo
United States

12.15 – 13.15
LUNCH BREAK
Lunch will be served at Shook Restaurant, Feast Village, Lower-Ground Floor.
14.45 – 15.00
**ROUNDTABLE: PHARMA COLLABORATION AND REGULATORY ISSUES**

Chair: David Margolis, University of North Carolina at Chapel Hill, United States

Panelists: Hiroyu Hatano, University of California, San Francisco, United States
Guenter Kraus, Tibotec/Janssen, Belgium
Veronica Miller, Forum for HIV Collaborative Research, United States
Charles Nicolette, Argos Therapeutics, United States
Bill Whittaker, National Association of People with HIV (NAPWA), Australia

Under embargo until 2 July 2013

14.45 – 15.00
**CHARACTERIZING THE RESERVOIR IN TISSUES AND T CELL SUBSETS**

Co-Chairs: John Frater, University of Oxford, United Kingdom
Christine Rouzioux, Université Paris Descartes, France

14.45 – 15.00
**OA2-1**
Targeting HIV-1 persistence in CD4 T memory stem cells by pharmaceutical inhibition of beta-catenin

M. Buzon, H. Sun, C. Li, E. Martin-Gayo, A. Shaw, E. Rosenberg, F. Pereyra, B. Walker, X. Yu,
M. Lichterfeld
United States
Under embargo until 2 July 2013

15.00 – 15.15
**OA2-2**
Longitudinal analysis of infection frequencies and genetic make-up of intracellular HIV-1 from tissue compartments during long-term suppressive therapy

S. Eriksson, L. Josefsson, E. Sinclair, H. Hatano, W. Shao, P. Hunt, M. Somsouk, P. Bacchetti,
S. Deeks, P. Lemey, F. Hecht, S. Palmer
Sweden, Australia

15.15 – 15.30
**OA2-3**
Identification and characterization of CD4 T cells actively transcribing HIV RNA in peripheral blood

J. Casazza, A. Vostel, D. Ambrozak, B. Hill, E. Boritz, D. Douek, R. Koup
United States
Under embargo until 1 July 2013
15.30 – 15.45

OA2-4
In vivo analysis of the replication capacity and pathogenic potential of HIV primary isolates from an elite suppressor
M. Swanson, M. Salgado, C. Pohlmeyer, R. Buckheit III, J. Blankson, J.V. Garcia-Martinez
United States

15.45 – 16.00

OA2-5 LB
BIT225, a novel inhibitor of HIV-1 release from HIV-1 reservoirs of the myeloid lineage
J. Wilkinson, C. Luscombe, G. Ewart, S. Kerr, N. Tanliang, W. Ratanasuwan, R. Murphy, M. Miller
Australia

16.00 – 16.15

OA2-6 LB
Gag-positive reservoir cells are identified by a new technique and are susceptible to HIV-specific cytotoxic T lymphocyte
E. Graf, M. Pace, L. Lynch, S. Deeks, S. Migueles, U. O’Doherty
United States
Under embargo until 3 July 2013

16.15 – 16.30

OA2-7 LB
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC trial
United Kingdom
Under embargo until 3 July 2013

16.30 – 18.30

POSTER EXHIBITION AND NETWORKING SESSION

All poster abstract presenters will be present for the poster exhibition session to discuss their abstracts and answer any questions. There will be an open bar and cocktail snacks during the networking session.
Programme

SUNDAY 30TH JUNE

9.00 – 10.30
KICK AND KILL: NOVEL APPROACHES TO REVERSING LATENCY AND IMMUNE CLEARANCE
Co-Chairs: Timothy Henrich, Brigham and Women’s Hospital & Harvard Medical School, United States
Julian Elliott, The Alfred Hospital, Monash University and Burnet Institute, Australia

9.00 – 9.30
Overview Speaker
Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial
Martin Tolstrup, Aarhus University, Denmark

9.30 – 9.45
OA3-1
Activation of the Wnt pathway by natural ligands or small molecule inhibitors activates latent HIV
H. Rafati, V.D.D. Lennert, M. El-Sayyed, C. Boucher, T. Mahmoudi
The Netherlands

9.45 – 10.00
OA3-2
Inducing HIV-1 in latently infected T cells with an autologous full length HIV-1 representing the majority intrapatient virus population
E. Arts, Y. Gao, D. Canaday, T. Biru, G. Nickel, M. Quinones-Mateu
United States

10.00 – 10.15
OA3-3
Destruction of the residual active HIV-1 reservoir by Env-specific immunotoxin
United States
Under embargo until 2 July 2013

10.15 – 10.30
OA3-4 LB
Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells
Australia

10.30 – 11.00 Coffee Break
11.00 – 12.30
CLINICAL INTERVENTIONS TARGETING THE HIV RESERVOIR
Co-Chairs: Ole S. Søgaard, Aarhus University Hospital, Denmark
Jean-Pierre Routy, McGill University, Canada

11.00 – 11.30
Overview Speaker
Towards cure in clinical trials?
Christine Katlama, Paris 6 University Hospital Pitié-Salpêtrière, France

11.30 – 12.00
OA4-1
Impact of 12-month HAART on cell-associated HIV-DNA in acute primary HIV-1 infection in the OPTIPRIM ANRS 147 trial
A. Chéret, G. Nembot, V. Avettand-Fenoël, A. Mélard, I. Ravaux, B. Hoen,
C. Lascoux-Combe, M.-L. Chaix, C. Tamalet, P. Yeni, F. Raffi, L. Slama, C. Katlama,
A. Venet, B. Autran, A. Saéz-Cirion, L. Meyer, C. Rouzioux
France
Under embargo until 3 July 2013

11.45 – 12.00
OA4-2
In chronically HIV-1 infected patients long-term antiretroviral therapy initiated above 500 CD4/mm³ achieves better HIV-1 reservoir depletion and T-cell restoration
L. Hocqueloux, V. Avettand-Fenoël, T. Prazuck, A. Mélard, E. Legac, M. Niang, C. Mille,
J. Buret, C. Rouzioux, “Coordinated Action on HIV Reservoirs” (AC32) of the ANRS
(Agence Nationale de Recherches sur le Sida et les hépatites virales)
France
Under embargo until 3 July 2013

12.00 – 12.15
OA4-3 LB
Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1: A Phase-1b clinical study of humanized monoclonal antibody KD-247 (KD-1002)
S. Matsushita, K. Yoshimura, T. Maeda, T. Murakami, KD-1002 Principal Investigators
and The Protocol Team of Quintiles
Japan

12.15 – 12.30
OA4-4 LB
In Depth Investigation of Peripheral and Gut HIV-1 Reservoirs, HIV-Specific Cellular Immunity, and Host Microchimerism following Allogeneic Hematopoetic Stem Cell Transplantation
A. LaCasce, P. Armand, R. Soiffer, M. Altfeld, D. Kuritzkes
United States
Under embargo until 3 July 2013
12.30 – 13.30
LUNCH BREAK
Lunch will be served at Shook Restaurant, Feast Village, Lower-Ground Floor.

13.30 – 15.00
ROUNDTABLE: ETHICS AND PATIENT EXPECTATIONS
Chair: Jintanat Ananworanich, The Thai Red Cross AIDS Research Centre, Thailand
Panelists: Jeremy Sugarman, John Hopkins Berman Institute of Bioethics, United States
Laurindo Garcia, B-Change Group, Philippines
Bruno Spire, Inserm, France
Rowena Johnston, amfAR, United States
Sharon Lewin, The Alfred Hospital, Monash University & Burnet Institute, Australia
Eric Fleutelot, Sidaction, France

15.00 – 15.30   Coffee Break

15.30 – 16.30
CLOSING SESSION
Co-Chairs: Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France
Jack Whitescarver, NIH-OAR, United States

15.30 – 16.10
Closing Lecture
Towards a cure for HIV and HBV: many ways, one aim.
Massimo Levrero, Università la Sapienza, Italy

16.10 – 16.30
IAS-ANRS Young Investigator Prize Ceremony
Co-Chairs: Jean-François Delfraissy, ANRS, France
Françoise Barré-Sinoussi, IAS President

The US$2,000 IAS/ANRS Young Investigator Award will be awarded to an abstract presenter at the symposium. The award is jointly funded by the IAS and the Agence Nationale de Recherche sur le sida et les hépatites virales (ANRS) to support young researchers who demonstrate innovation, originality, rationale and quality in the field of HIV/AIDS research.
A1 – HIV AND SIV DIVERSITY

1. Positive Selection and Functional Effects of Amino Acid Substitutions in Tat exon 1 during Primary HIV-1C Infection
   Botswana, United States

A5 – ENTRY (ATTACHMENT, RECEPTORS AND CO-RECEPTORS, PENETRATION AND TROPISM)

2. HIV-1 entry and trans-infection in astrocytes: implications for cure and eradication
   Australia

A8 – REGULATION OF VIRAL GENE EXPRESSION AND REPLICATION

3. Suppression of HIV-1C virus production in human PBMCs by dsRNA induced Chromatin remodeling of LTR promoter
   India

A9 – CELLULAR FACTORS NECESSARY FOR HIV REPLICATION

4. Restriction of HIV-1 infection in dendritic cells avoids induction of IFN-α-mediated responses and reduces chemokine expression. Impact on viral escape and establishment of CD4 reservoirs
   Spain

5. Involvement of Human Topoisomerase II isoforms in the Strand transfer events of HIV-1 Reverse Transcription
   S. Lokeswara Balakrishna, A.K. Kondapi.
   India

A10 – CELLULAR AND TISSUE RESERVOIRS

6. Efficient infection of healthy donors’ monocyte derived macrophages by erythrocyte-associated HIV
   Argentina

7. Erythrocyte-associated HIV in a model of HIV infection
   Argentina

8. Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments
   France

9. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy
   France

10. T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection
    France
A11 – MECHANISMS OF HIV PERSISTENCE

11. HIV-1 resistance mutations by ultradepth pyrosequencing in proviral DNA of patients at success of a first line ART

12. Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens
   L. Bertoni Giron, S. Tenore, R. Gabriel, M.C. Araripe Sucupira, R. Sobie Diaz. Brazil

A13 – STRATEGIES TO TARGET AND ERADICATE RESERVOIRS

13. Archived HIV-1 CTL Epitopes and HLA I Alleles of Patients at Success of a First Line ART: Toward a New Concept of Curative Vaccine

14. Establishment of Macaque CD4+ T Cells and CD34+ Hematopoietic Stem Cells resistant to SIV Infection using Zinc Finger Nucleases Technology
   M.-C. E. Gauduin, P. Lentz, G. Bonello, M. Salas, M. Cepeda, R. White. United States

15. Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function

16. Combination of proteasome and Hsp90 inhibitors induces autophagic cell death in HIV-1-infected macrophages and CD4+ T cells: approaches to elimination of the virus reservoirs
   A. Kabakov, Y. Makarova, K. Budagova. Russian Federation

17. Maraviroc (MVC) intensification can activate NFkB through CCR5 and the expression of its target genes in resting CD4+-T-cells in suppressed HIV-1-infected patients
   N. Madrid-Elena, B. Hernandez-Novoa, L. Garcia-Bermejo, S. Moreno. Spain

Late Breaker

18. Metal Nanoparticles Reduce Intracellular HIV-1 Replication and Stimulate Growth of HIV-1 Infected PBMC
   S.K. Prakash. India

19. HIV Resistance to Dolutegravir (DTG) Simultaneously Diminishes Viral DNA Integration into Host Cells and Viral Replication Fitness: Implications for HIV Reservoirs
   T. Mesplede, P. Quashie, M. Oliveira, M. Wainberg. Canada

A14 – MUCOSAL TRANSMISSION

20. The intestinal microenvironment affects the susceptibility of DCs to HIV-1
   M. Cavarelli, B. Fusetti, K. Tsilingiri, M. Rescigno, G. Scarlatti. Italy

Under embargo until 3 July 2013
A18 – INNATE SENSORS OF HIV

21. Female genital epithelial cells from HIV-exposed seronegative commercial sex workers express a discrete cytokine/chemokines profile upon toll-like receptor activation

N. Dil, J. Kimani, M. Kimani, F.A. Plummer, T.B. Ball.
Canada

A19 – INTRINSIC CELLULAR DEFENCES AND RESTRICTION FACTORS


Japan

23. Increased levels of APOBEC3 and interferon mRNA in PBMC of Highly Exposed Seronegatives Individuals (HESN)

Mexico

A20 – IFN-I (VIRAL INHIBITION, IMMUNOMODULATORY FUNCTIONS)

24. Characterization of HIV-1 Gag and Nef T cell Responses in an HIV-1 infected Kenyan Population

R. Langat, J. Indangasi, B. Farah, O. Anzala, KAVI-TEAM.
Kenya

A21 – NK CELLS AND DENDRITIC CELLS

25. Analysis of NK cell receptor-ligand expression in the prevention of AIDS-defining opportunistic infections in patients with low CD4+ T cell count

Italy

26. DC infected by the ANRS MVAHIV vaccine candidate primes NK cells with anti-HIV specific activity through a mechanism involving NKG2D and NKP46 on NK cells, and membrane-bound IL-15 on DC

France

Under embargo until 2 July 2013

A22 – MONOCYTES AND MACROPHAGES

27. HIV-1 stimulates Human Monocytes to produce BAFF through Type I IFN and its secretion level shows sex-related differences

Canada

28. HIV-1 virion accumulation and ATP-Induced release in human primary monocyte-derived macrophages

Italy
A24 – ANTIBODY DIVERSITY AND FUNCTION

29. Generation and characterization of neutralizing anti-V3 scFvs against HIV-1 clade C
   R. Kumar, R. Kumari, R. Andrabi, A. Tiwari, L. Khan, M. Makhdoomi, A. Nair, S. Kumar, N. Wig, S. Sinha, K. Luthra.
   India

30. Antibody and T cell response to the protease cleavage sites drive extensive mutations and correlated with protection against higher dose of SIVmac239 challenge and disease progression in Cynomolgus macaques
   Canada

A27 – CELLULAR IMMUNITY

31. Assessing the Role of Antigen-Specific CD8+ T cells in Delayed Progression to AIDS
   M.M. Herman, L.R. McKinnon, S. Kiazyk, F.A. Plummer, T.B. Ball.
   Canada

32. HIV-1 Env-specific conformational ADCC epitopes: potential utility for HIV vaccine design
   V. Madhavi, M. Kramski, L. Wren, R. Center, S. Kent, I. Stratov.
   Australia

33. HIV-1 infection reduces emigration of mature thymocytes from the human thymus by downregulation of the sphingosine-1-kinase receptor S1PR1
   United States
   Under embargo until 1 July 2013

A28 – MUCOSAL IMMUNITY

34. Severe depletion and exhaustion of mucosal-associated invariant T (MAIT) cells in HIV-1 infected patients
   J. van Lunzen, P. Hartjen, D. Ebert, I. Toth, C. Beisel, J. Schulze zur Wiesch.
   Germany

A29 – VIRAL DETERMINANTS OF PATHOGENESIS

35. NEF-mediated down-regulation of MHC I expression in thymocytes may affect the pathogenicity of a pediatric isolate of X4 HIV-1.
   United States

A30 – ACUTE AND EARLY HIV/SIV INFECTION

36. Analysis of HLA-restricted HIV-specific CD8 T cell responses and viral adaptation in patients with acute HIV infection prior to full seroconversion
   Australia

A41 – ELITE CONTROLLERS

37. An elite controller in pregnancy - towards a definition of recovery, though not cure?
   Singapore
38. HIV-1 Vif- and Nef-responses in controllers present higher magnitude and target more conserved, less promiscuous epitopes than responses seen in typical progressors
   Brazil

A42 – ASYMPTOMATIC LONG TERM NON-PROGRESSORS, HIV-2, ANIMAL MODELS OF SPONTANEOUS CONTROL

39. Preservation of gut mucosal NK cells secreting IL-22 and IL-17 is associated with slow disease progression in SIV-infected Chinese rhesus macaques
   United States

A44 – HIGHLY EXPOSED SERONEGATIVE INDIVIDUALS (HESN)

40. Polymorphisms in the IRF1 gene associated with reduced HIV susceptibility and their impact on plasma and cervical lavage cytokine/chemokine expression
   A. Siyao, R.-C. Su, J. Lajoie, J. Kimani, W. Jaoko, K. Fowke, F. A. Plummer, T. B. Ball.
   Canada

A45 – CORRELATES OF PROTECTION

41. Functional cure after long term HAART initiated during early HIV infection – a comprehensive case study
   Germany

A46 – HIV DRUG DEVELOPMENT

42. Evaluation of a panel of selective inhibitors of PKC θ or Lck for controlling HIV-1 replication in CD4+ T cells
   Spain

43. Safety and Efficacy study of a herbal concoction used for alternative/complementary treatment of HIV infection in Nigeria
   Nigeria

A47 – MECHANISMS OF ANTI-RETROVIRAL DRUG RESISTANCE

44. The real cause of increasing HIV opportunistic infections in CHUK (Kigali University Teaching Hospital)
   D. S. Habimana, Medical Students-Team Study Group.
   Rwanda

45. Secondary resistance mutations in the R263K integrase inhibitor resistance pathway
   T. Mesplede, M. A. Wares, N. Osman, P. K. Quashie, Y. Han, D. N. Singhroy, M. A. Wainberg.
   Canada

A49 – NUCLEIC ACID BASED HIV AND SIV THERAPY DEVELOPMENT

46. Characterization of a new use for acyclovir and tenofovir using human cervico-vaginal tissue ex vivo
   C. Vanpouille, A. Introini, A. Lisco, J.-C. Grivel, J. Balzarini, L. Margolis.
   United States
A50 – DESIGN OF APPROACHES TARGETING INFLAMMATION/IMMUNE ACTIVATION

47. Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals

A51 – HIV-HEPATITIS VIRUS INTERACTIONS

48. Hepatitis B virus coinfections: Prevalence and CD4 profile among patients on comprehensive care services in Kenya

A52 – TUBERCULOSIS AND OTHER MYCOBACTERIA

49. Anti-mycobacterial activity is enhanced by blocking the Tim3-Galectin 9 interaction in HIV patients

B56 – THERAPEUTIC VACCINE AND IMMUNE BASED THERAPY TRIALS

50. cART reduces antibody-dependent cellular cytotoxicity to HIV: Implications for Therapeutic Vaccines
   V. Madhavi, S. Jegaskanda, R. Center, F. Ana Sosa Batiz, J. Ananworanich, D. Cooper, A. Kelleher, D. Hsu, M. Kramski, S. Kent. Australia
   Late Breaker

B58 – 5-DRUG HAART DURING PRIMARY HIV INFECTION LEADS TO A REDUCTION OF PROVIRAL DNA LEVELS IN COMPARISON TO LEVELS ACHIEVABLE DURING CHRONIC INFECTION

51. 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection

D24 – IMPACT OF FINANCIAL CRISIS ON THE HIV FUNDING AND RESPONSE

52. Building the Path to the End of AIDS: How investments in HIV prevention research and development responded to the global economic downturn, new research results and funding trends 2000-2012
The IAS would like to thank the Programme Committee members for all their support in organizing the 2013 Towards an HIV Cure Symposium.

Françoise Barré-Sinoussi (Chair),
Inserm and Institut Pasteur, France

Steve Deeks (Co-Chair),
University of California, San Francisco, USA

Sharon Lewin (Co-Chair),
The Alfred Hospital, Monash University and Burnet Institute, Australia

Jintanat Ananworanich,
The Thai Red Cross AIDS Research Centre, Thailand

Paula Cannon,
University of Southern California, USA

Nicolas Chomont,
VGTI-Florida, USA

Adeeba Kamarulzaman,
University of Malaya, Malaysia

Richard Koup,
NIAID, USA

Daniel Kuritzkes,
Brigham and Women’s Hospital/Harvard Medical School, USA

David Margolis,
University of North Carolina at Chapel Hill, USA

Doug Richman,
University of California, San Diego, USA

Bruno Spire,
Inserm, France
<table>
<thead>
<tr>
<th>SATURDAY 29TH JUNE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:15 Welcome Remarks</td>
</tr>
<tr>
<td>9:15 - 9:55 Opening Address</td>
</tr>
<tr>
<td>9:55 - 10:10 CNIHR Award Ceremony</td>
</tr>
<tr>
<td>10:10 - 10:30 Break</td>
</tr>
<tr>
<td>10:30 - 12:15 Cellular sensing and regulation of HIV Production</td>
</tr>
<tr>
<td>12:15 - 13:15 Lunch</td>
</tr>
<tr>
<td>13:15 - 14:45 Roundtable:</td>
</tr>
<tr>
<td>Pharma Collaboration, regulation and Regulatory Issues</td>
</tr>
<tr>
<td>14:45 - 16:30 Characterizing the reservoir in tissues and T cell subsets</td>
</tr>
<tr>
<td>16:30 - 18:30 Poster Exhibition &amp; Networking Session</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUNDAY 30TH JUNE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 10:30 Kick and Kill: novel approaches to reversing latency and immune clearance</td>
</tr>
<tr>
<td>10:30 - 11:00 Break</td>
</tr>
<tr>
<td>11:00 - 12:30 Clinical interventions targeting the HIV reservoir</td>
</tr>
<tr>
<td>12:30 - 13:30 Lunch Break</td>
</tr>
<tr>
<td>13:30 - 15:00 Roundtable:</td>
</tr>
<tr>
<td>Ethics and patient expectations</td>
</tr>
<tr>
<td>15:00 - 15:30 Break</td>
</tr>
<tr>
<td>15:30 - 16:10 Closing Lecture</td>
</tr>
<tr>
<td>16:10 - 16:30 IAS-ANRS Prize and Closing Remarks</td>
</tr>
</tbody>
</table>